Black Rock Inc. Solid Biosciences Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.51 - $7.56 $15,676 - $232,379	-30,738 Reduced 1.07%	2,837,899 $1.33 Million
Q2 2022 Aug 12, 2022	SELL	$0.43 - $1.24 $1.27 Million - $3.66 Million	-2,953,624 Reduced 50.73%	2,868,637 $1.77 Million
Q1 2022 May 12, 2022	SELL	$0.74 - $1.79 $318,901 - $771,396	-430,948 Reduced 6.89%	5,822,261 $6.99 Million
Q4 2021 Feb 10, 2022	BUY	$1.69 - $2.46 $2.94 Million - $4.28 Million	1,741,514 Added 38.6%	6,253,209 $10.9 Million
Q3 2021 Nov 09, 2021	BUY	$2.38 - $3.77 $1.05 Million - $1.67 Million	442,960 Added 10.89%	4,511,695 $10.8 Million
Q2 2021 Aug 11, 2021	BUY	$3.49 - $5.51 $14.2 Million - $22.4 Million	4,068,735 New	4,068,735 $14.9 Million

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $22.7M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.